Michelle L. Basil - Sep 15, 2022 Form 4 Insider Report for HAEMONETICS CORP (HAE)

Role
EVP and General Counsel
Signature
/s/ Michelle L. Basil
Stock symbol
HAE
Transactions as of
Sep 15, 2022
Transactions value $
-$1,431,870
Form type
4
Date filed
9/19/2022, 04:39 PM
Previous filing
Jun 15, 2022
Next filing
Sep 21, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HAE Common Stock Options Exercise $429K +11.2K +27.45% $38.43 51.8K Sep 15, 2022 Direct F1, F2
transaction HAE Common Stock Options Exercise $593K +14.2K +27.48% $41.64 66K Sep 15, 2022 Direct F1, F2
transaction HAE Common Stock Options Exercise $179K +3.17K +4.81% $56.57 69.2K Sep 15, 2022 Direct F1, F2
transaction HAE Common Stock Sale -$2.16M -27.8K -40.13% $77.76 41.4K Sep 15, 2022 Direct F1, F2, F3
transaction HAE Common Stock Sale -$473K -6.03K -14.55% $78.50 35.4K Sep 15, 2022 Direct F1, F2, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HAE Non-qualified Stock Option (Right to Buy) Options Exercise $0 -11.2K -76.3% $0.00 3.46K Sep 15, 2022 Common Stock 11.2K $38.43 Direct F1, F5
transaction HAE Non-qualified Stock Option (Right to Buy) Options Exercise $0 -14.2K -77.16% $0.00 4.21K Sep 15, 2022 Common Stock 14.2K $41.64 Direct F1, F5
transaction HAE Non-qualified Stock Option (Right to Buy) Options Exercise $0 -3.17K -18.96% $0.00 13.6K Sep 15, 2022 Common Stock 3.17K $56.57 Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction pursuant to an existing 10b5-1 trading plan.
F2 This number includes unvested restricted stock units ("RSUs") previously reported.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.33 to $78.30, inclusive. The reporting person undertakes to provide to Haemonetics Corporation ("Haemonetics"), any security holder of Haemonetics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3) and (4) to this Form 4.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.33 to $78.85, inclusive.
F5 Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.